CD73 inhibitors present significant opportunities in cancer immunotherapy by reversing immunosuppression in tumors and enhancing immune response. Novel antibodies, RNA, and small molecules are in ...
TSLP inhibitors and receptor antagonists present significant market opportunities for treating various inflammatory diseases due to their ability to modulate key inflammatory pathways. Expanding ...
Chronic neuropathic pain remains one of the most challenging conditions to treat, with current therapies offering limited ...
First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline –– Announced FDA Approval of VEPPANU™ ...
(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...
Health and Me on MSN
US FDA approves Merck’s once-daily combination pill for treating adults with HIV
According to the latest data from UNAIDS, 40.8 million people globally were living with HIV in 2024. Of these, 39.4 million ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...
Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, ...
Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the ...
"Product revenue reached $1.5 billion in the quarter, representing 34% year-over-year growth" and "we now project 2026 revenue to be between $6.3 billion to $6.5 billion, an increase of $100 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results